Biomerieux SA

The global bloodstream infection testing market is projected to grow from USD 876.49 million in 2025 to USD 1,404.68 million by 2035, at a compound annual growth rate of 4.80 percent. Blood culture held a dominant 78.8 percent share by sample type in 2025, while whole blood molecular testing is expected to grow fastest due to rapid pathogen detection in two to six hours. By technology, microbiological testing accounted for 55 percent of the market in 2025, but molecular diagnostics is the fastest-growing segment, driven by multiplex PCR platforms that identify pathogens and resistance genes within one to two hours. North America led the market in 2025, with the United States contributing approximately 87.4 percent of regional revenues, while Asia Pacific is the fastest-growing region, led by China's 44.8 percent share of regional revenues. Recent developments include QIAGEN's launch of a CE-IVDR-certified panel for bloodstream infection pathogen and antimicrobial resistance marker identification in about one hour, and bioMerieux's CE marking for a rapid blood culture identification test.

bioMérieux has introduced GENE-UP TYPER SLM, a new real-time PCR assay designed to support rapid root cause analysis by discriminating Salmonella in food industry environments. The test specifically targets Salmonella enterica subspecies enterica, the subspecies most frequently isolated in human salmonellosis cases and food-related incidents. It runs on the GENE-UP system and, after DNA extraction and amplification, results are uploaded to the AUGMENTED-DX web portal, where machine learning assigns a unique strain address and groups identical strains into clusters to trace contamination sources. The launch follows the early 2025 introduction of a Listeria monocytogenes assay on the same platform. Mérieux NutriSciences holds co-exclusive rights to perform testing in key geographies for outsourced services, and the kit is now available worldwide.